Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 259

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Extended Valganciclovir Prophylaxis to Prevent Cytomegalovirus After Lung Transplantation: A Randomized, Controlled Trial

Palmer, Scott M., Limaye, Ajit P., Banks, Missy, Gallup, Dianne, Chapman, Jeffrey, Lawrence, E. Clinton, Dunitz, Jordan, Milstone, Aaron, Reynolds, John, Yung, Gordon L., Chan, Kevin M., Aris, Robert, Garrity, Edward, Valentine, Vincent, McCall, Jonathan, Chow, Shein-Chung, Davis, Robert Duane, Avery, Robin · 2010 · Annals of Internal Medicine

Abstract

BACKGROUND: Cytomegalovirus (CMV) is the most prevalent opportunistic infection after lung transplantation. Current strategies do not prevent CMV in most at-risk patients. OBJECTIVE: To determine whether extending prophylaxis with oral valganciclovir from the standard 3 months to 12 months after lung transplantation is efficacious. DESIGN: Randomized, clinical trial. Patients were randomly assigned by a central automated system to treatment or placebo. Patients and investigators were blinded to treatment status. (ClinicalTrials.gov registration number: NCT00227370) SETTING: Multicenter trial involving 11 U.S. lung transplant centers. PATIENTS: 136 lung transplant recipients who completed 3 months of valganciclovir prophylaxis. INTERVENTION: 9 additional months of oral valganciclovir (n = 70) or placebo (n = 66). MEASUREMENTS: The primary end point was freedom from CMV disease (syndrome or tissue-invasive) on an intention-to-treat basis 300 days after randomization. Secondary end points were CMV disease severity, CMV infection, acute rejection, opportunistic infections, ganciclovir resistance, and safety. RESULTS: CMV disease occurred in 32% of the short-course group versus 4% of the extended-course group (P < 0.001). Significant reductions were observed with CMV infection (64% vs. 10%; P < 0.001) and disease severity (110 000 vs. 3200 copies/mL, P = 0.009) with extended treatment. Rates of acute rejection, opportunistic infections, adverse events, CMV UL97 ganciclovir-resistance mutations, and laboratory abnormalities were similar between groups. During the 6 months after study completion, a low incidence of CMV disease was observed in both groups. LIMITATION: Longer-term effects of extended prophylaxis were not assessed. CONCLUSION: In adult lung transplant recipients who have received 3 months of valganciclovir, extending prophylaxis by an additional 9 months significantly reduces CMV infection, disease, and disease severity without increased ganciclovir resistance or toxicity. A beneficial effect with regard to prevention of CMV disease seems to extend at least through 18 months after transplantation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7326/0003-4819-152-12-201006150-00003

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 259

Metadata

Authors
Palmer, S. M., Limaye, A. P., Banks, M., Gallup, D., Chapman, J., Lawrence, E. C., Dunitz, J., Milstone, A., Reynolds, J., Yung, G. L., Chan, K. M., Aris, R., Garrity, E., Valentine, V., McCall, J., Chow, S.-C., Davis, R. D., & Avery, R.
Venue
Annals of Internal Medicine
Published
2010-06-15
Volume
152
Issue
12
Pages
761-769
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W2145871241
Cited by
259
References
14
FWCI
17.19
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Extended Valganciclovir Prophylaxis to Prevent Cytomegalovirus After Lung Transplantation: A Randomized, Controlled Trial. https://app.cochat.ai/papers/10.7326/0003-4819-152-12-201006150-00003
The paper
Palmer, S. M., Limaye, A. P., Banks, M., Gallup, D., Chapman, J., Lawrence, E. C., Dunitz, J., Milstone, A., Reynolds, J., Yung, G. L., Chan, K. M., Aris, R., Garrity, E., Valentine, V., McCall, J., Chow, S.-C., Davis, R. D., & Avery, R. (2010). Extended Valganciclovir Prophylaxis to Prevent Cytomegalovirus After Lung Transplantation: A Randomized, Controlled Trial. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-152-12-201006150-00003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.